What do systematic reviews say?

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avoralstat vs placebo

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cisapride vs placebo

The review found no eligible studies for this question.

• Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical mydriatics vs intracameral mydriatics

Topical mydriatics showed no clear difference in AE: cystoid macular edema ‐ any time point during or after surgery compared with intracameral mydriatics (low certainty).

• Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.01, 7.83]
  1 study · 555 participants
  Low

Topical mydriatics vs depot delivery systems

The review found no eligible studies for this question.

• Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical mydriatics vs intracameral mydriatics

Topical mydriatics showed no clear difference in AE: posterior capsule rupture—any time point during or after surgery compared with intracameral mydriatics (low certainty).

• Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.01, 7.83]
  1 study · 555 participants
  Low

Bovine colostrum vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Synsorb Pk vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Urtoxazumab (3.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 8.14]
  1 study · 71 participants
  Very low

Urtoxazumab (1.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.06, 14.59]
  1 study · 74 participants
  Very low

Antibiotics vs no treatment

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing delirium in hospitalised non‐ICU patients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Non‐pharmacological interventions for preventing delirium in hospitalised non‐ICU patients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 351 participants
  Low

Intervention not reported

• Non‐pharmacological interventions for preventing delirium in hospitalised non‐ICU patients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 6 participants
  Very low

Pre‐dilution vs post‐dilution (as defined by study investigators)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Long (> 20 cm) vs short (≤ 20 cm) catheter

It is very uncertain whether long (> 20 cm) changes death from any cause at day 28 of compared with short (≤ 20 cm) catheter (very low certainty).

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  RR 1.38 [0.61, 3.11]
  1 study · 94 participants
  Very low

CVVHD vs CVVH or CVVHDF

It is very uncertain whether CVVHD changes death from any cause compared with CVVH or CVVHDF (very low certainty).

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  RR 0.77 [0.42, 1.4]
  4 studies · 229 participants
  Very low

Surface‐modified vs standard catheter

It is very uncertain whether surface‐modified changes death from any cause at day 28 of compared with standard double‐lumen catheter with identical geometry and flow design (very low certainty).

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  RR 1.08 [0.76, 1.53]
  1 study · 236 participants
  Very low

Polyethylenimine‐treated membrane (AN69ST) vs other membranes

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found